Background: Chronic hand eczema (CHE) is a debilitating dermatologic condition often refractory to topical corticosteroids (TCS).Although oral alitretinoin has demonstrated efficacy in CHE, real-world multicenter data in Korean populations remain limited.Objective: To evaluate the real-world efficacy and safety of oral alitretinoin in Korean patients with severe CHE with insufficient response to TCS.Methods: This multicenter, prospective, open-label study enrolled 146 patients with severe CHE at tertiary hospitals in Korea.Patients received oral alitretinoin (30 mg once daily, with dose reduction to 10 mg permitted) for up to 24 weeks, with observation up to 36 weeks.The primary endpoint was achievement of "clear" or "almost clear" on the Physician's Global Assessment (PGA) at treatment completion.Secondary endpoints included the modified total lesion symptom score (mTLSS) and Patient's Global Assessment (PaGA).Safety was evaluated by monitoring adverse events (AEs) and laboratory abnormalities.Efficacy analyses were performed on the full analysis set (n=129).
Kwon et al. (Thu,) studied this question.